Cargando…

Symptom aggravation after withdrawal of metal chelating agent therapy in patients with Wilson's disease

OBJECTIVE: To study the aggravation of clinical symptoms after discontinuation of metal chelating agent therapy in Wilson's disease (WD) patients, analyze the causes of aggravation, and observe the prognosis. METHODS: 40 WD patients (cerebral type 30 cases and hepatic type 10 cases) who stopped...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Xiangxue, Liao, Jian, Liu, Yinjie, Qin, Haolin, Xiao, Xia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10498091/ https://www.ncbi.nlm.nih.gov/pubmed/37491953 http://dx.doi.org/10.1002/brb3.3170

Ejemplares similares

Combination Therapy Using Chelating Agent and Zinc for Wilson’s Disease
por: Chen, Jui-Chi, et al.
Publicado: (2015)

Hypopituitarism in Wilson’s disease resolved after copper-chelating therapy
por: Dauth, Nina, et al.
Publicado: (2021)

The Effect of Chelation Therapy on the Amino Aciduria and Peptiduria of Wilson's Disease
por: Asatoor, A. M., et al.
Publicado: (1983)

Hyaluronate/black phosphorus complexes as a copper chelating agent for Wilson disease treatment
por: Kim, Seong-Jong, et al.
Publicado: (2021)

Chelating Agents and the Regulation of Metal Ions
por: Bulman, Robert A.
Publicado: (1994)

Clinical and Genetic Analysis in Neurological Wilson’s Disease Patients With Neurological Worsening Following Chelator Therapy
por: Hou, Haiman, et al.
Publicado: (2022)

Wilson Disease in Children; Chelation Therapy or Liver Transplantation? A 10-Year Experience from Pakistan
por: Aaraj, Sahira, et al.
Publicado: (2021)

Advances on Chelation and Chelator Metal Complexes in Medicine †
por: Kontoghiorghes, George J.
Publicado: (2020)

Role of chelating agents for prevention, intervention, and treatment of exposures to toxic metals.
por: Goyer, R A, et al.
Publicado: (1995)

Chelation in Metal Intoxication
por: Flora, Swaran J.S., et al.
Publicado: (2010)

Recent Developments in Metal-Based Drugs and Chelating Agents for Neurodegenerative Diseases Treatments
por: Sales, Thais A., et al.
Publicado: (2019)

Chelating agents in biological systems.
por: Schubert, J
Publicado: (1981)

Antioxidant and Metal Chelation-Based Therapies in the Treatment of Prion Disease
por: Brazier, Marcus W., et al.
Publicado: (2014)

Liposomes containing chelating agents. Cellular penetration and a possible mechanism of metal removal
Publicado: (1975)

N-Acetyl-Cysteine as Effective and Safe Chelating Agent in Metal-on-Metal Hip-Implanted Patients: Two Cases
por: Giampreti, Andrea, et al.
Publicado: (2016)

Intestinal expression of metal transporters in Wilson’s disease
por: Przybyłkowski, Adam, et al.
Publicado: (2013)

Bismuth chelate as a contrast agent for X-ray computed tomography
por: Fu, Ji-jun, et al.
Publicado: (2020)

Chelation of toxic metals: current interests.
por: Goyer, R A
Publicado: (1995)

Chelation therapy after the Trial to Assess Chelation Therapy: results of a unique trial
por: Avila, Maria D., et al.
Publicado: (2014)

Reversible lesions in the brain parenchyma in Wilson's disease confirmed by magnetic resonance imaging: earlier administration of chelating therapy can reduce the damage to the brain
por: Kozić, Duško B., et al.
Publicado: (2014)

On the Anticataractogenic Effects of L-Carnosine: Is It Best Described as an Antioxidant, Metal-Chelating Agent or Glycation Inhibitor?
por: Abdelkader, Hamdy, et al.
Publicado: (2016)

Endocrine Symptoms as the Initial Manifestation of Wilson’s Disease
por: Krysiak, Robert, et al.
Publicado: (2012)

Biosensors with Metal Ion–Phosphate Chelation Interaction for Molecular Recognition
por: Ma, Xiaohua, et al.
Publicado: (2023)

The asymmetry of neural symptoms in Wilson's disease patients detecting by diffusion tensor imaging, resting‐state functional MRI, and susceptibility‐weighted imaging
por: Zhou, Xiang‐xue, et al.
Publicado: (2018)

Electroconvulsive therapy for mania associated with Wilson disease: Improvement in psychiatric and motor symptoms
por: Antonio Bozutti, Luis, et al.
Publicado: (2021)

Chelating agents and cadmium toxicity: problems and prospects.
por: Nordberg, G F
Publicado: (1984)

Interaction of chelating agents with cadmium in mice and rats.
por: Eybl, V, et al.
Publicado: (1984)

Alteration of tissue disposition of cadmium by chelating agents.
por: Klaassen, C D, et al.
Publicado: (1984)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
por: Lee, Ji Won, et al.
Publicado: (2013)

Arsenic intoxication: general aspects and chelating agents
por: Bjørklund, Geir, et al.
Publicado: (2020)

Chelating agents for diluted geothermal brine reinjection
por: Cobos, Jacquelin E., et al.
Publicado: (2022)

A High-Calorie Diet Aggravates Mitochondrial Dysfunction and Triggers Severe Liver Damage in Wilson Disease Rats
por: Einer, Claudia, et al.
Publicado: (2018)

Paramagnetic Metal Accumulation in the Deep Gray Matter Nuclei Is Associated With Neurodegeneration in Wilson’s Disease
por: Yuan, Xiang-Zhen, et al.
Publicado: (2020)

New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology
por: Tornesello, Anna Lucia, et al.
Publicado: (2017)

Chelating Agents in Soil Remediation: A New Method for a Pragmatic Choice of the Right Chelator
por: Nurchi, Valeria Marina, et al.
Publicado: (2020)

Preparation of Amidoxime Polyacrylonitrile Chelating Nanofibers and Their Application for Adsorption of Metal Ions
por: Huang, Fenglin, et al.
Publicado: (2013)

Rationale for the Successful Management of EDTA Chelation Therapy in Human Burden by Toxic Metals
por: Ferrero, Maria Elena
Publicado: (2016)

Misdiagnosis of Wilson's Disease in a Patient with Psychiatric Symptoms
por: Nimisha, Doval, et al.
Publicado: (2016)

Preparation of barium sulfate chelating agent DTPA-5Na and molecular dynamics simulation of chelating mechanism
por: Ma, Chao, et al.
Publicado: (2023)

Metal chelates as anti-cancer agents. II cytotoxic action of palladium and platinum complexes of 6-mercaptopurine and thioguanine.
por: Das, M., et al.
Publicado: (1978)

Cannot write session to /tmp/vufind_sessions/sess_0rpio7a9k4h4428ov39vpm5fh9